COCH Stock Catalyst: Envoy Medical Receives FDA Approval for Final Trial Stage of Cochlear Implant

Oct 6, 2025 · 3:59pm ET

The company is now set to proceed with the next phase of its clinical trials.

Max move

+226.5%

High of day $2.71

Sparker timei

3:59pm ET

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Envoy Medical announced on October 25, 2023 FDA approval for final trial stage of cochlear implant trial.

The announcement cited $10M-$15M.

Envoy Medical, Inc. Class A Common Stock has a free float of 18,132,000 shares and 28,786,500 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time COCH sparks.

Catch the next COCH-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.